These results strongly validate the present strategy to control the modality of the EGF molecule at the nanoparticle surface in the development of more potent and efficient EGF-GNP conjugates, and further suggest the SR-GNPs as a candidate for cancer therapy. This evidence concerns the gene EGF and cancer.